Contribution of ABL Kinase Domain Mutations to Imatinib Resistance in Different Subsets of Philadelphia-Positive Patients: By the GIMEMA Working Party on Chronic Myeloid Leukemia-Reference-Cited by-同舟云学术

Contribution of ABL Kinase Domain Mutations to Imatinib Resistance in Different Subsets of Philadelphia-Positive Patients: By the GIMEMA Working Party on Chronic Myeloid Leukemia

Published:2006-12-15 Issue:24 Volume:12 Page:7374-7379
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Soverini Simona,Colarossi Sabrina,Gnani Alessandra,Rosti Gianantonio,Castagnetti Fausto,Poerio Angela,Iacobucci Ilaria,Amabile Marilina,Abruzzese Elisabetta,Orlandi Ester,Radaelli Franca,Ciccone Fabrizio,Tiribelli Mario,di Lorenzo Roberto,Caracciolo Clementina,Izzo Barbara,Pane Fabrizio,Saglio Giuseppe,Baccarani Michele,Martinelli Giovanni

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 427 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dose Justification for Asciminib in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia with and Without the T315I Mutation;Clinical Pharmacokinetics;2024-09-07

2. Retrospective analysis of own long-term experience in studying the BCR::ABL kinase domain mutational status in patients with chronic myeloid leukemia;Oncohematology;2024-09-01

3. Therapeutic options for chronic myeloid leukemia following the failure of second-generation tyrosine kinase inhibitor therapy;Frontiers in Oncology;2024-07-29

4. Second-generation tyrosine kinase inhibitors in chronic myeloid leukemia today: efficacy and safety;Meditsinskiy sovet = Medical Council;2024-07-25

5. Chemotherapy-free treatment of VAF induces early and deep molecular response in patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: a prospective, single-center, single-arm, phase 2 trial;2024-07-12